# IMPROVING VACCINATION FOR ALL PEOPLE

## About DCVMN
DCVMN is a voluntary, non-governmental, nonpartisan, not-for-profit, public health driven alliance of vaccine manufacturers, research and policy organizations from all over the world.

## Our mission
To protect all people against known and emerging infectious diseases by improving the availability of high-quality vaccines globally.

## Our objective
To provide a consistent and sustainable supply of quality and affordable vaccines to developing countries.

## Our approach
DCVMN member companies cooperate to increase and maintain the number of WHO prequalified vaccines available for international procurement. DCVMN maintains a dialogue with stakeholders to help manufacturers access the knowledge, tools and skills required to attain and maintain WHO prequalification status.

## Areas of focus
DCVMN strengthens developing country vaccine manufacturers by:

- providing information & training on technical improvements;
- fostering technology transfer initiatives;
- educating the public about the availability of safe and effective vaccines from developing world manufacturers and related programs; and
- providing a platform for meaningful public-private dialogue on immunization, manufacturing, regulatory and supply-related issues.
DCVMN IN NUMBERS

DCVMN members include 43 vaccine manufacturers in 14 countries/territories.

DCVMN members produce over 40 different types of vaccines, in several presentations and using a variety of technology platforms, totaling around 200 products.

74 vaccines produced by 15 DCVMN members have been prequalified by WHO over the past 25 years.

In 2018, DCVMN members supplied over 50% of the 2.36 billion doses of vaccines procured by UNICEF globally.

Since 2013, nearly 2300 professionals have attended regional training workshops organized by DCVMN and its partners. Over 4000 more have benefitting from in-house follow-up trainings.

Since 2012, DCVMN and its partners have organized 52 webinars, reaching over 2200 professionals.

2141 professionals enrolled in courses, and 948 earned course certificates on the DCVMN e-learning platform in 2018, representing a three-fold increase compared to 2017.
SAVING LIVES THROUGH VACCINE INNOVATION: A SNAPSHOT OF THE LAST 10 YEARS

DCVMN members have been helping to improve public health for decades. Their achievements include many ‘world’s firsts’.

- The first fully liquid Pentavalent (DTwPHepBHib) as well as the first fully liquid Hexavalent vaccine, based on whole-cell pertussis vaccine, were developed, manufactured and launched by Panacea Biotec in India in 2008 and 2017, respectively.
- The first Meningitis A vaccine developed specifically for use in Africa was manufactured by Serum Institute of India and prequalified by WHO in 2010.
- The first commercially available Hepatitis E vaccine was developed by Innovax and approved in China in 2012.
- The first conjugated typhoid vaccine was developed and manufactured by Bharat Biotech in India. It was launched in 2013 and prequalified by WHO in 2017.
- The first Sabin-based IPV vaccine was developed by IMBCAMS and approved in China in 2015.
- The first cell-based influenza vaccine for children prequalified by WHO was developed by SK Biologics in Korea and manufactured since 2015.
- The first and second EV-71 vaccines against Foot-Hand and Mouth disease were developed by IMBCAMS and Sinovac, in China and launched in 2015 and 2016.
- The first oral cholera vaccine to be available in plastic containers was produced by EuBiologics in Korea and prequalified by WHO in 2017.
- The first thermostable rotavirus vaccine, developed by Serum Institute of India, became available in 2017.
LOOKING AHEAD:
PRIORITY INITIATIVES 2019 – 2021

Following extensive consultations with members, DCVMN identified six initiatives to help support DCVMs over the next two years.

- **Expand training programs**
  - Expand current QMS programs to include training on GMP, GCP, GLP, GDP, PV.

- **Sharing of best-practices**
  - Foster peer-to-peer communication through expert working groups.

- **Regulatory Convergence**
  - Advance regulatory convergence by supporting new approaches on a regional basis.

- **Pharmacovigilance**
  - Support pharmacovigilance (PV) projects to enhance vaccine safety monitoring.

- **Collaborations**
  - Increase access to international expert consultants for needed ad hoc support.

- **New Technology**
  - Engage manufacturers on new technology adoption through the DCVMN Annual General Meeting.
SEEKING LEARNING OPPORTUNITIES?
Visit the DCVMN e-learning portal to access 11 online courses free of charge.

moodle.dcvmn.net

INTERESTED IN JOINING THE DCVMN COMMUNITY?

Become a corporate member  Serve as a resource member
Become a corporate partner  Join our consultants’ portal

www.dcvmn.org